[Cooperative phase II study of epirubicin (EPI) in bladder cancer, renal pelvic and ureteral tumors--Urological Cooperative Study Group of EPI].
A phase II study of a new anthracycline anti-cancer antibiotics, epirubicin (EPI), was undertaken in 71 patients with urothelial malignancies; 40 with advanced urothelial malignancies and 31 with superficial bladder cancer. Out of them 32 patients with advanced stage of urothelial cancer were evaluated for the systemic use of EPI, while 30 patients with superficial bladder cancer for intravesical use. Intravenous administration of this new anticancer antibiotic, at a dosage of 60 mg/m2 every three weeks, showed the response rate of 20.0% for advanced bladder cancer and 14.3% for renal pelvic and ureteral tumors. In cases of superficial bladder cancer, at a dosage of 60 mg/30 ml X 3 day every week in principal, the response rate was 66.7%. Eight out of 30 patients showed complete disappearance of the tumor. Twelve patients also showed more than 50% tumor regression. As for adverse effects no serious cardiotoxicity was demonstrated. Anorexia and other gastrointestinal side effects, such as nausea and vomiting, were also seen. Alopecia and myelosuppression were the major adverse effects among patients with systemic EPI administration. With intravesical use of EPI, cystitis syndrome was the major toxicity. However, no systemic side effects were noted in these cases. In conclusion, EPI was assumed to be effective for the treatment of advanced urothelial tumors and superficial bladder cancer.
Niijima
T
T
Department of Urology, Faculty of Medicine, the University of Tokyo
Koyanagi
T
T
Department of Urology, Hokkaido University School of Medicine
Maru
A
A
Department of Urology, Hokkaido University School of Medicine
Sakashita
S
S
Department of Urology, Hokkaido University School of Medicine
Koiso
K
K
Department of Urology, Institute of Clinical Medicine, University of Tsukuba
Ishikawa
H
H
Department of Urology, Institute of Clinical Medicine, University of Tsukuba
Uchida
K
K
Department of Urology, Institute of Clinical Medicine, University of Tsukuba
Shimazaki
J
J
Department of Urology, School of Medicine, Chiba University
Isaka
S
S
Department of Urology, School of Medicine, Chiba University
Akaza
H
H
Department of Urology, Faculty of Medicine, the University of Tokyo
Machida
T
T
Department of Urology, The Jikei University School of Medicine
Tashiro
K
K
Department of Urology, The Jikei University School of Medicine
Nakagami
Y
Y
Department of Urology, First Hospital of Nippon Medical School
Lin
T
T
Department of Urology, First Hospital of Nippon Medical School
Hosaka
M
M
Department of Urology. Yokohama City University School of Medicine
Kubota
Y
Y
Department of Urology. Yokohama City University School of Medicine
Obata
K
K
Department of Urology, Nagoya Second Red Cross Hospital
Kobayashi
H
H
Department of Urology, Nagoya Second Red Cross Hospital
Sonoda
T
T
Department of Urology, Osaka University School of Medicine
Matsuda
M
M
Department of Urology, Osaka University School of Medicine
Fujioka
H
H
Department of Urology, Osaka University School of Medicine
Kotake
T
T
Department of Urology, The Center for Adult Diseases, Osaka
Kuroda
M
M
Department of Urology, The Center for Adult Diseases, Osaka
Ohmori
H
H
Department of Urology, Okayama University Medical School
Matsumura
Y
Y
Department of Urology, Okayama University Medical School
Tsushima
T
T
Department of Urology, Okayama University Medical School
Uyama
T
T
Department of Urology, National Hospital Shikoku Cancer Center
Kumazawa
J
J
Department of Urology, Faculty of Medicine, Kyushu University
Ueda
T
T
Department of Urology, Faculty of Medicine, Kyushu University
Ohi
Y
Y
Department of Urology, Faculty of Medicine. Kagoshima University
Shimoinaba
T
T
Department of Urology, Faculty of Medicine. Kagoshima University
D000368:Aged; D000855:Anorexia / Q000139:chemically induced; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D015251:Epirubicin; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D007680:Kidney Neoplasms / Q000188:drug therapy*; D007682:Kidney Pelvis; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D014516:Ureteral Neoplasms / Q000188:drug therapy*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D006454:Hemoglobins; D015251:Epirubicin; D004317:Doxorubicin